** U.S.-listed shares of biotech company Regencell Bioscience RGC.O rise 21.3% to $72.80 after the bell
** Company says its 38-for-one forward stock split, announced on June 2, has taken effect
** Each shareholder of the company, at the close of business on June 12, will receive 37 additional shares for every share held on the record date - Regencell said on June 2
** "The forward stock split is intended to enhance liquidity in the market for the company's ordinary shares and make the shares more accessible to investors" - RGC
** RGC develops traditional Chinese medicine for the treatment of neurocognitive disorders
** Up to last close, stock more than tripled YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.